CompletedPhase 4NCT00611039

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy

Studying Antisynthetase syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Germans Trias i Pujol Hospital
Principal Investigator
Bonaventura Clotet, MD,PhD
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Intervention
Darunavir 900mg + ritonavir 100 mg once a day(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
2008 – 2009

Study locations (1)

Collaborators

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00611039 on ClinicalTrials.gov

Other trials for Antisynthetase syndrome

Additional recruiting or active studies for the same condition.

See all trials for Antisynthetase syndrome →

← Back to all trials